December 09, 2016 7:26 PM ET


Company Overview of Provectus Biopharmaceuticals, Inc.

Company Overview

Provectus Biopharmaceuticals, Inc., a biopharmaceutical company, engages in developing ethical pharmaceuticals for oncology and dermatology indications. Its prescription drug candidates includes PV-10, which is in Phase III study for cutaneous melanoma; completed Phase II study for metastatic melanoma; completed Phase I study for liver and breast cancers; and phase 1b/2 study for pembrolizumab. The company is also developing PH-10 that has completed Phase II randomized study for the treatment of psoriasis and atopic dermatitis. In addition, it develops PH-10 for the treatment of actinic keratosis and severe acne vulgaris. Further, the company is developing over-the-counter pharmaceuticals, i...

7327 Oak Ridge Highway

Suite A

Knoxville, TN 37931

United States

Founded in 2002

3 Employees





Key Executives for Provectus Biopharmaceuticals, Inc.

Interim Chief Executive Officer, Chief Operating Officer and Secretary
Age: 57
Total Annual Compensation: $700.0K
President and Director
Age: 58
Total Annual Compensation: $700.0K
Chief Technology Officer and Director
Age: 53
Total Annual Compensation: $700.0K
Compensation as of Fiscal Year 2015.

Provectus Biopharmaceuticals, Inc. Key Developments

Provectus Biopharmaceuticals, Inc. Announces Agreement with POETIC to Study Potential of PV-10 for Pediatric Cancer

Provectus Biopharmaceuticals, Inc. and POETIC, The Pediatric Oncology Experimental Therapeutics Investigators Consortium, a group of 10 top-tier academic medical centers developing new pediatric cancer therapies, announced a joint research agreement focused on pediatric applications of PV-10, an investigational ablative immunotherapy, as a potential treatment for childhood cancers. The program will involve collaboration with a number of NCI Cancer Centers that are part of the POETIC group including Memorial Sloan Kettering Cancer Center (MSK), Alberta Children’s Hospital, and other top-tier cancer centers of excellence. PV-10 is an injectable formulation of Rose Bengal that is under investigation as an ablative immunotherapy for solid tumor cancers. Provectus has received orphan drug designations of PV-10 from the FDA for melanoma and hepatocellular carcinoma indications. The company is conducting a Phase 3 clinical trial of PV-10 for locally advanced cutaneous melanoma.

Provectus Biopharmaceuticals, Inc. Presents at LD Micro Main Event 2016, Dec-06-2016 10:30 AM

Provectus Biopharmaceuticals, Inc. Presents at LD Micro Main Event 2016, Dec-06-2016 10:30 AM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Blvd, Los Angeles, CA 90049, United States.

Provectus Biopharmaceuticals, Inc. to Report Q3, 2016 Results on Nov 14, 2016

Provectus Biopharmaceuticals, Inc. announced that they will report Q3, 2016 results on Nov 14, 2016

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Provectus Biopharmaceuticals, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at